Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

Bcl-2 and p53 gene products have been both linked to cell death by apoptosis. In the present study, we examined the relationship of Bcl-2 and p53 protein expression, p53 mutation and apoptosis in normal human ovaries and different types of human ovarian epithelial tumors by immunohistochemical localization, in situ terminal transferase-mediated dUTP nick end labeling and polymerase chain reaction-single strand conformation polymorphism. It was found that Bcl-2 expressed strongly in the surface epithelium of normal ovaries and benign and borderline ovarian tumors but weakly in the malignant tumors. On the contrary, strong protein expression of p53 was found in 54% (25/46) of the malignant epithelial tumors examined but similar expression of p53 was not observed in borderline and benign tumors and normal ovarian surface epithelium. A significant inverse correlation between Bcl-2 and p53 expression was found in the malignant ovarian tumors examined. p53 gene mutation at exons 5-11 was however not a pre-requisite for p53 expression in both borderline and malignant tumors. Apoptotic activities, as reflected by apoptotic indices, were low in normal ovarian surface epithelium and benign tumors but were increased in borderline and malignant tumors, with the highest average apoptotic index found in grade III malignant tumors. Statistical analyses showed a positive correlation between apoptosis and p53 expression, but similar correlation was not found between apoptosis and Bcl-2 expression. Our results also indicate that although expression of Bcl-2 is important during ovarian carcinogenesis, the Bcl-2 protein may have other roles to play apart from being a modulator of apoptosis in human ovarian epithelial cancers.

[1]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[2]  F. Gruijl,et al.  bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. , 1997, Archives of dermatology.

[3]  J C Reed,et al.  The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. , 1995, Oncogene.

[4]  S. Korsmeyer,et al.  bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. , 1994, Development.

[5]  J. Lee,et al.  bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. , 1995, Cancer research.

[6]  S. Hirohashi,et al.  High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy , 1992, Japanese journal of cancer research : Gann.

[7]  John Calvin Reed Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[8]  G. Elia,et al.  Bcl‐2 proto‐oncogene expression in epstein‐barr‐virus‐associated nasopharyngeal carcinoma , 1993, International journal of cancer.

[9]  S. Cannistra Medical progress : cancer of the ovary , 1993 .

[10]  R. Berkowitz,et al.  SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. , 1996, Oncogene.

[11]  A. Villanueva,et al.  K‐ras mutations in mucinous ovarian tumors , 1997, Cancer.

[12]  P. Sevelda,et al.  DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. , 1995, Gynecologic oncology.

[13]  G. Tortolero-Luna,et al.  The epidemiology of ovarian cancer , 1995, Journal of cellular biochemistry. Supplement.

[14]  R. Knapp,et al.  Unifocal origin of advanced human epithelial ovarian cancers. , 1992, Cancer research.

[15]  H. Hartung,et al.  Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[16]  M. Itabashi,et al.  Expression of Bcl‐2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis , 1997, Pathology international.

[17]  C. Croce,et al.  DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Goldblum,et al.  Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis , 1999, American Journal of Gastroenterology.

[19]  R. Berkowitz,et al.  p53 gene mutation in human borderline epithelial ovarian tumors. , 1994, Journal of the National Cancer Institute.

[20]  M. Clarke,et al.  Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells. , 1998, Molecular genetics and metabolism.

[21]  Yi-Song Wang,et al.  Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. , 1993, Oncogene.

[22]  R. Bast,et al.  Molecular approaches to prevention and detection of epithelial ovarian cancer , 1995, Journal of cellular biochemistry. Supplement.

[23]  G. Baretton,et al.  bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. , 1996, American journal of clinical pathology.

[24]  John Calvin Reed,et al.  Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.

[25]  L. Verburgt,et al.  Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. , 1996, American journal of respiratory cell and molecular biology.

[26]  S. Korsmeyer,et al.  Bcl-2 protein expression during murine development. , 1994, The American journal of pathology.

[27]  S. Grénman,et al.  Immunohistochemically detected p53 and HER‐2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas , 1997, Cancer.

[28]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[29]  N. Harris,et al.  Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma. , 1996, American journal of clinical pathology.

[30]  A. Baldini,et al.  DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer , 1998, Oncogene.

[31]  John Calvin Reed,et al.  Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.

[32]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[33]  S. Syrjänen,et al.  Implications of the p53 tumor-suppressor gene in clinical oncology. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Louis,et al.  Human gliomas with wild-type p53 express bcl-2. , 1995, Cancer research.

[35]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[36]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Jochemsen,et al.  Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis. , 1995, Carcinogenesis.

[38]  R. Berkowitz,et al.  Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. , 1993, Cancer research.

[39]  A. Okamoto,et al.  Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. , 1991, Cancer research.

[40]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[41]  M. Rugge,et al.  bcl‐2 and p53 immunophenotypes in pre‐invasive, early and advanced oesophageal squamous cancer , 1997, Histopathology.

[42]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[43]  C. Potten,et al.  Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. , 1996, British Journal of Cancer.

[44]  R. Warnke,et al.  Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. , 1993, The American journal of pathology.

[45]  D. Easton,et al.  Contribution of BRCA1 mutations to ovarian cancer. , 1997, The New England journal of medicine.

[46]  C. Kittas,et al.  Immunohistochemical detection of p53 protein in HPV positive oral lesions. , 1998, Anticancer research.

[47]  Y. Homma,et al.  Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. , 1997, The Journal of urology.

[48]  L. Donehower,et al.  Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. , 1994, Oncogene.

[49]  M. Karpeh,et al.  Immunohistochemical evaluation of bcl‐2 protein expression in gastric adenocarcinomas , 1995, Cancer.

[50]  C. Croce,et al.  Down-regulation of bcl-2 by p53 in breast cancer cells. , 1994, Cancer research.

[51]  A. Wyllie,et al.  The genetic regulation of apoptosis. , 1995, Current opinion in genetics & development.

[52]  W. Chan,et al.  Apoptosis and Bcl‐2 oncoprotein expression in the human fetal central nervous system , 1998, The Anatomical record.

[53]  P. Lipponen,et al.  Apoptosis in bladder cancer as related to standard prognostic factors and prognosis , 1994, The Journal of pathology.

[54]  E. Wilander,et al.  Expression and prognostic significance of Bcl-2 in ovarian tumours. , 1995, British Journal of Cancer.

[55]  S. Thorgeirsson,et al.  Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  S. Korsmeyer,et al.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Boyd,et al.  p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix. , 1996, Gynecologic oncology.

[58]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[59]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[60]  M. Higashiyama,et al.  High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. , 1995, Anticancer research.

[61]  H. Kitchener,et al.  p53 mutation is a common genetic event in ovarian carcinoma. , 1993, Cancer research.